AmpliPhi BioSciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced study results for a trial looking at a novel treatment strategy for cystic fibrosis (CF) patients. The results, which suggested that bacteriophages remain active against Pseudomonas aeruginosa (P. aeruginosa)…
News
The Cystic Fibrosis Trust recently announced its first-ever appointment of a “Director of Impact” to spearhead the organization’s commitment to improve care, support and research for those with CF in the United Kingdom. Dr. Keith Brownlee boasts a proven record of experience and expertise as a cystic fibrosis specialist pediatrician, having worked for more than 20…
Vertex Pharmaceuticals Incorporated recently announced in a press release new data on its long-term PROGRESS study testing the investigational regimen ORKAMBI (lumacaftor/ivacaftor) for cystic fibrosis (CF). The data was presented at the 38th European Cystic Fibrosis Society (ECFS) Conference, June 10-13, 2015 held in Brussels, Belgium in…
New research is shedding light on a possible link between endometriosis in females who have cystic fibrosis. Cystic fibrosis (CF) is a genetic disorder caused by mutations to the cystic fibrosis transmembrane conductance regulator (CFTR) gene that mostly affects the lungs, but also the pancreas, liver, kidneys and intestine. The…
Internationally recognized Cystic Fibrosis expert and State University of New York at Buffalo clinical professor of pediatrics Drucy S. Borowitz, MD has received the 2015 Stockton Kimball Award for outstanding scientific achievement and service She accepted the honor at a May 28 SUNY Buffalo School of Medicine and…
The lead drug candidate under development by Celtaxsys — an Atlanta, Georgia based clinical-stage development company focused on novel therapeutics for treating inflammatory disease through regulation of immune cell migration and activation — is CTX-4430, described as a potent, oral, once-daily, small-molecule LTA4 Hydrolase (LTA4H) inhibitor that shows promise as…
Vertex Pharmaceuticals Incorporated  and Parion Sciences recently announced a joint collaboration for the development of investigational epithelial sodium channel (ENaC) inhibitors to treat cystic fibrosis (CF) and other pulmonary conditions. Based on the agreement rights, Vertex will develop and commercialize Parion’s ENaC inhibitors, named P-1037 and P-1055, for…
The U.K. based Cystic Fibrosis Trust, a national charity that funds research into the disease and provides information and support for patients and families, has announced that the nonprofit organization will standardize using DocuSign for Digital Transaction Management in order to eliminate printing, faxing, scanning and overnighting documents in…
The selection of articles I chose for this week is an attempt to capture recent events, along with one older article, showcasing the range of articles relating to the science and increased awareness being brought to the CF community ‘Salty Girls’ photo Series Challenges Notions of Beauty and Cystic Fibrosis…
Celtaxsys has announced that the company’s phase 2 clinical trial to evaluate CTX-4430, its investigational treatment for cystic fibrosis (CF), will be supported by a $5 million grant from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT). The CFFT is the non-profit drug discovery and development affiliate of the Cystic Fibrosis…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.